PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc SUNFISH Part 2 Risdiplam (RG7916) Results - Corporate Call Transcript

Feb 06, 2020 / 01:00PM GMT
Release Date Price: €47.8
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the PTC Therapeutics call to review Part 2 of SUNFISH Clinical Trial Data at the SMA EU Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Head of Investor Relations, Alex Kane. Thank you. Please go ahead, sir.

Alex Kane
PTC Therapeutics, Inc. - IR Officer

Thank you, and hello, everybody. Welcome to the PTC Therapeutics conference call to review the SUNFISH Part 2 clinical trial data that was presented earlier today at the SMA Europe Conference.

Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements regarding the advancement of our joint collaboration program with Roche and the SMA Foundation and any related potential regulatory submissions, regulatory approvals or commercial prospects. These statements are subject to risks and to uncertainties that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot